Intermittent hypoxic-hyperoxic training (IHHT)

There is genuine human controlled data, but not for longevity. The strongest available study (Bahenský et al. context aside, the key trial is the German long COVID study, PMC11634465) was a prospective, controlled, OPEN-TREATMENT, NON-RANDOMISED pilot in 145 inpatients at a single German rehabilitation centre. The IHHT arm (n=70) improved 6-minute walk distance 2.8-fold more than standard care (91.7 m vs 32.6 m, p<0.001), with secondary gains in stair-climbing power, dyspnoea, fatigue, quality of life and handgrip. The authors themselves state the design had limited strength due to absence of blinding and non-random assignment, producing baseline imbalance between groups. So: this is deconditioned post-viral patients regaining function during a five-week inpatient rehab programme, not healthy adults gaining healthspan. What the evidence does NOT show: any effect on mortality, biological age, epigenetic clocks, or any longevity or healthspan endpoint; any benefit in healthy or asymptomatic people; any durability beyond the treatment window. The mitochondrial-rejuvenation and anti-ageing claims made in clinic marketing are mechanistic extrapolation, not demonstrated outcomes. Safety signals appear benign in supervised use, though the "no reported adverse events" claim cited by at least one Australian provider rests on an unpublished 2015 literature review, which is not verifiable evidence. Note also that provision in Australia sits mainly with naturopathic and wellness practices rather than medical longevity clinics, which is itself informative about how the intervention is positioned.

What it is

Plain-language explainer

Categories

Common questions

What is Intermittent hypoxic-hyperoxic training (IHHT)?

There is genuine human controlled data, but not for longevity. The strongest available study (Bahenský et al. context aside, the key trial is the German long COVID study, PMC11634465) was a prospective, controlled, OPEN-TREATMENT, NON-RANDOMISED pilot in 145 inpatients at a single German rehabilitation centre. The IHHT arm (n=70) improved 6-minute walk distance 2.8-fold more than standard care (91.7 m vs 32.6 m, p<0.001), with secondary gains in stair-climbing power, dyspnoea, fatigue, quality of life and handgrip. The authors themselves state the design had limited strength due to absence of blinding and non-random assignment, producing baseline imbalance between groups. So: this is deconditioned post-viral patients regaining function during a five-week inpatient rehab programme, not healthy adults gaining healthspan. What the evidence does NOT show: any effect on mortality, biological age, epigenetic clocks, or any longevity or healthspan endpoint; any benefit in healthy or asymptomatic people; any durability beyond the treatment window. The mitochondrial-rejuvenation and anti-ageing claims made in clinic marketing are mechanistic extrapolation, not demonstrated outcomes. Safety signals appear benign in supervised use, though the "no reported adverse events" claim cited by at least one Australian provider rests on an unpublished 2015 literature review, which is not verifiable evidence. Note also that provision in Australia sits mainly with naturopathic and wellness practices rather than medical longevity clinics, which is itself informative about how the intervention is positioned.

How strong is the evidence for Intermittent hypoxic-hyperoxic training (IHHT)?

Commercial. It is offered and sold, which is a statement about availability, not about efficacy.

Is Intermittent hypoxic-hyperoxic training (IHHT) approved in Singapore?

variis has no Health Sciences Authority position on file for Intermittent hypoxic-hyperoxic training (IHHT). Absence of a recorded position is not approval.

Is Intermittent hypoxic-hyperoxic training (IHHT) approved in Australia?

Therapeutic Goods Administration position on record: NOT INDEPENDENTLY VERIFIED - treat as a distributor claim, not as established fact. The Australian ReOxy distributor states on its own site, verbatim: "ReOxy device is entered in the Australian Register of Therapeutic Goods (ARTG 408421)". I was unable to confirm this against the TGA's own register: tga.gov.au/resources/artg/408421 timed out on repeated attempts and the ARTG search interface was unreachable in this session, so the sponsor, device class and, critically, the registered intended purpose remain unconfirmed. An ARTG entry, if it exists, would establish only that the device may lawfully be supplied in Australia for its registered intended purpose; it would NOT constitute TGA endorsement of anti-ageing, longevity or healthspan claims. Separately, none of the Australian provider pages reviewed (Tsavo Wellness, The Orchard, Rosalba Courtney) make any TGA or ARTG claim at all, and The Orchard positions ReOxy explicitly as a wellness service rather than a medical treatment. BEFORE PUBLICATION: the ARTG number 408421 must be checked directly against the TGA register and the registered intended purpose quoted.. An evidence grade and a regulatory approval are different questions.

What else is Intermittent hypoxic-hyperoxic training (IHHT) called?

Also known as IHHT, Intermittent hypoxia hyperoxia therapy, ReOxy, Intermittent hypoxic-hyperoxic therapy, Altitude training at sea level, Hypoxic training, Interval hypoxic training.